AstraZeneca stock price forecast: Bullish setup continues as AZN holds above moving averages

Traders Union
All News
Financial News
AstraZeneca rises 0.97% to $15168.00

Highlights

AstraZeneca reported significant progression-free survival improvement in unresectable hepatocellular carcinoma from its Imfinzi-Imjudo, lenvatinib, and TACE combination in the Phase III EMERALD-3 trial.
The company also released mixed late-stage results for efzimfotase alfa in hypophosphatasia and positive results for tozorakimab in COPD.
Shares command strong bullish momentum above major technical supports, with a projected five-day range of $14,700.00 to $15,400.00 and high probability of further upside.

Positive trial results and pipeline updates drive mixed investor sentiment

AstraZeneca has reported positive high-level results from the Phase III EMERALD-3 trial, where its Imfinzi and Imjudo combination with lenvatinib and TACE showed a significant improvement in progression-free survival for patients with unresectable hepatocellular carcinoma. The company also released mixed data from a phase three study of efzimfotase alfa for hypophosphatasia and reported positive late-stage results for tozorakimab in COPD. Additionally, AstraZeneca updated its issued share capital figures and approved the admission of 491 new ordinary shares for employee share schemes.

Buyer dominance holds as price nears highs amid overbought signals

On the technical front, AZN’s current price is clearly above short, medium, and long-term moving averages (MA-20, MA-50, and MA-200), with support established at the Ichimoku Kijun level ($14,510.00). While RSI signals a buy, both Stoch RSI and CCI are in overbought territory; the daily MACD, ADX, and Awesome Oscillator all remain neutral. BBP is strongly positive, reflecting sustained buyer dominance, as price trades close to the session high and intraday volatility remains elevated.

Consolidation favored with upside potential amid strong buy signals

Over the next five days, the typical volatility band is expected between $14,700.00 and $15,400.00, with the price likely to consolidate above major moving averages. The probability of a price increase is above 80%, based on multiple 'Buy' or 'Strong Buy' weekly indicators, suggesting that a decline is less likely. A bullish scenario would emerge if AZN breaches $15,400.00, which could attract renewed buying, while a break below $14,700.00 would prompt a correction toward the Kijun support.

Viktoras Karapetjanc, expert at Traders Union, sees AstraZeneca’s current strength as a combination of positive clinical updates and impressive technical positioning. He notes that the stock’s move above all major moving averages and strong sentiment after recent trial results support a bullish outlook. The analyst believes that elevated buyer confidence and well-supported technicals raise the odds of further price appreciation. Karapetjanc is watching for a breakout above $15,400.00 as a key trigger. "With fundamentals and sentiment aligning so strongly, I expect AstraZeneca to continue its upward path in the coming sessions."

Earlier, analysts noted that AstraZeneca maintained a strong bullish technical structure supported by positive clinical developments and sustained momentum. The addition of encouraging trial results in oncology and ongoing technical strength supports further upside potential, with the next decisive move likely to come on a clear break above $15,400.00.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.